The general purpose of intensive insulin regimens is to achieve postprandial glucose control. Short-acting insulin analogs were originally designed to fit this premise by synchronizing plasma insulin increase and food absorption ([@B1]). They are indeed absorbed more quickly than regular human insulin. However, this was demonstrated in normal-weight healthy subjects or lean subjects with type 1 diabetes in studies assessing small subcutaneous injections (i.e., 4--12 units) ([@B2][@B3]--[@B4]). Paradoxically, few studies ([@B5],[@B6]) have either assessed such dosages or been conducted in overweight subjects with or without type 2 diabetes, although clinical practice shows that most patients with type 2 diabetes on insulin are distinctly overweight or obese and on much larger insulin dosages ([@B7],[@B8]).

Multiple factors affect insulin absorption including its physicochemical properties, excipients, concentration, and dosage as well as the clinical conditions under which it is injected, e.g., orthostatic position, injection site, depth, exercises, massage, temperature, and smoking ([@B1],[@B4],[@B9],[@B10]). Injected volume ([@B11]) and subcutaneous adipose tissue blood flow (ATBF) are two other major absorption factors ([@B12],[@B13]). Although it is well recognized that ATBF is dramatically altered in obese insulin-resistant individuals and in subjects with type 2 diabetes, baseline values are 50--70% lower than values for lean healthy subjects and physiological postprandial doubling is blunted ([@B14],[@B15]). Nonetheless, most studies have been conducted in lean subjects.

In view of the above, we hypothesized that absorption rate and activity of short-acting insulin analogs would be substantially lower in obese subjects with type 2 diabetes than pharmacokinetics reported in the literature. This study thus assessed the pharmacokinetic and pharmacodynamic responses of obese subjects with type 2 diabetes to subcutaneous injections of lispro at incrementally larger dosages (10, 30, and 50 units) during euglycemic clamps.

RESEARCH DESIGN AND METHODS
===========================

Study design
------------

This single-dose single-blinded controlled three-way randomized sequential study in subjects with type 2 diabetes was conducted at the clinical research center.

Nonsmoking patients aged 18--75 years, with a BMI ≥30 kg/m^2^ and an A1C ≤10%, taking over 100 units insulin daily, with or without oral hypoglycemic agents, were recruited. All were asked to maintain a stable diet and physical activity level between experiments and to refrain from strenuous exercise, alcohol, and caffeine intake for 48 h before each experiment.

The experimental protocol was duly approved by the Research Ethics Committee, conducted according to the Declaration of Helsinki principles, and all subjects signed the consent form.

Protocol
--------

Experiments were performed 3 weeks apart in randomized order (10, 30, or 50 units). Subjects with type 2 diabetes were admitted at 8:00 [p.m.]{.smallcaps} on the evening preceding each experimental day, after having their evening meal and their usual insulin injection. An intravenous antecubital cannula was inserted into each arm: one for venous sampling and glucose measurements (Beckman Instruments, Diagnostic Systems Group, Brea, CA) and the other for dual administration of human insulin (Toronto R, Novo Nordisk Canada, Mississauga, ON) and dextrose as needed. Plasma glucose level was brought progressively into the normal target range (i.e., 5--6 mmol/l overnight).

Experiments started at 8:00 [a.m.]{.smallcaps} Anthropometric data were recorded: height, weight, and body composition by bioelectrical impedance (Tanita, Arlington Heights, IL). Subjects were kept fasting (drinking water permitted) during the entire 8-h clamp study. A venous catheter was retrogradely inserted into the hand of the same arm used for nighttime blood samplings, with the hand kept warm in a heating pad. Euglycemic clamp was performed after subcutaneous injection of lispro, 20 min after interruption of the overnight insulin infusion. Lispro was administered with a pen device (HumaPenErgo, Eli Lilly Canada, Toronto, ON) with an 8-mm needle (30 G × 0.3 × 8 mm) into subcutaneous adipose tissue 8 cm above the umbilicus and 10 cm from the medial line.

Plasma glucose was measured every 5 min to clamp glucose levels between 5 and 6 mmol/l with a 20% dextrose infusion via the antecubital catheter already in place. Blood samples were collected at 10-min intervals for the first 3 h and at 20-min intervals thereafter. Study procedures ended at 4:00 [p.m.]{.smallcaps} Subjects received a meal and their usual dose of insulin. They were discharged once glucose stabilized over 6 mmol/l.

Healthy control subjects were admitted on the experimental day at 7:30 [a.m.]{.smallcaps}, fasting from 8:00 [p.m.]{.smallcaps} the prior evening. Each received a single dose 10 units lispro; all other procedures were identical to those described above.

ATBF was measured once, on the first experimental day, in each subject using the gold standard method, i.e., the ^133^Xe washout technique, a routinely used technique in our hands ([@B16]). Briefly, ^133^Xe (Bristol-Myers Squibb Canada, Dorval, Quebec) was injected in the subcutaneous adipose tissue of the abdomen, at the opposite side of the insulin injection site. ATBF was measured quantitatively using a Mediscint System (John Caunt Scientific, Oxford, U.K.).

Sample analysis
---------------

Blood samples were collected in tubes containing sodium citrate and a protease inhibitor cocktail (Complete, EDTA-free; Roche Diagnostics, Mannheim, Germany). Blood was promptly centrifuged at 4°C, and the resultant plasma aliquots were frozen immediately in liquid nitrogen and stored at −80°C until assaying. Plasma lispro was measured in duplicate with a specific radioimmunoassay kit (Linco Research, St. Charles, MO).

Calculations and statistical analyses
-------------------------------------

Plasma lispro measurements were used to estimate absorption rate constant (ka), maximum plasma concentration (*C*~max~), time to maximal concentration (*T*~max~), area under the lispro plasma concentration curve (AUC~0-∞~), *C*~max~ to dose ratio (*C*~max~/*D*), AUC~0-∞~ to dose ratio (AUC~0-∞~/*D*), volume of distribution (Vz), clearance (Cl), half-life (*t*½), and mean residence time. Calculations were performed assuming a noncompartmental distribution using the WinNonlin 5.2 software (Pharsight, Mountain View, CA).

Using glucose infusion rate (GIR) versus time data, the maximum glucose infusion rate (GIR~max~), time to maximum glucose infusion rate (tGIR~max~), and total glucose infusion from injection to end of clamp (GI~tot~) were calculated.

The study comprised one experiment in healthy subjects and three in obese subjects with type 2 diabetes; in the latter subjects, 10-unit experiments were used as control for comparison with larger dosages. Results not normally distributed, based on the Normal Quintile Plot, were log-transformed for all statistical analyses and reported back-transformed in their original units. Values of *P* \< 0.05 were considered significant.

Fisher exact tests, for categorical variables, and unpaired *t* tests, for continuous variables, were used to compare characteristics between groups. Unpaired *t* tests were used for comparison between groups of pharmacokinetic and pharmacodynamic variables with 10-unit injections. Repeated-measures ANOVA tests were used to compare differences in pharmacokinetic and pharmacodynamic variables at different dosages in subjects with type 2 diabetes, with Tukey honestly significance difference tests for post hoc multiple comparisons.

For correlations between parameters that were repeatedly assessed at multiple insulin dosages in the same patients, repeated-measures ANOVA tests considering clustering of multiple measurements were used. All adjustments were performed again by multivariate ANOVA tests. Data calculations and statistical analyses were performed using JMP 7.0 software (SAS Institute, Cary, NC).

RESULTS
=======

Six healthy subjects and seven obese subjects with type 2 diabetes were enrolled (A1C 8.1 ± 1.2%, duration of diabetes 20.2 ± 8.6 years, insulin therapy 5.1 ± 4.2 years). Subjects with type 2 diabetes participated in all three experiments (10, 30, and 50 units). Their age, BMI, weight, and adiposity indexes were higher although ATBF was blunted ([Table 1](#T1){ref-type="table"}). Heart rate, blood pressure, and ATBF remained stable in both groups during experiments (data not shown).

###### 

Characteristics of study groups

                               Healthy subjects   Subjects with type 2 diabetes   *P*
  ---------------------------- ------------------ ------------------------------- ----------
  *n* (men/women)              6 (3/3)            7 (6/1)                         0.266
  Age (years)                  23.7 ± 2.4         60.3 ± 7.6                      \<0.0001
  BMI (kg/m^2^)                22.1 ± 1.4         38.3 ± 7.0                      0.0002
  Weight (kg)                  70.0 ± 7.6         111.0 ± 14.3                    0.0002
  Fat (%)                      22.4 ± 7.9         32.6 ± 5.1                      0.017
  Fat mass (kg)                15.4 ± 4.5         36.5 ± 9.6                      0.0005
  Fat-free mass (kg)           54.6 ± 10.2        74.5 ± 7.7                      0.002
  Total body water (kg)        40.0 ± 7.5         54.5 ± 5.7                      0.002
  ATBF (ml/min/100 g tissue)   4.2 ± 0.7          1.5 ± 0.5                       \<0.0001

Data are means ± SD.

After the 10-unit injection, the ratio *C*~max~/*D* was 41% lower (*P* \< 0.001) in subjects with type 2 diabetes than in healthy subjects, but *C*~max~, *T*~max~, AUC~0-∞~, AUC~0-∞~/*D*, ka, and Cl were similar in both groups. Mean residence time, Vz, and *t*½ tended to be greater in subjects with type 2 diabetes than in control subjects ([Fig. 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). After the 30- and 50-unit injections, ka dropped by 60% (*P* = 0.035) and *T*~max~ was delayed by 33 (*P* = 0.118) and 74 min (*P* \< 0.001), respectively. *C*~max~/*D*, Cl, Vz, and *t*½ were not affected by the dose, although mean residence time tended to be greater. *T*~max~ (*r*^2^ = 0.51, *P* = 0.0004), *C*~max~ (*r*^2^ = 0.90, *P* \< 0.0001), and AUC~0-∞~ (*r*^2^ = 0.94, *P* \< 0.0001) were associated with dosage.

![Mean (± SD) plasma lispro concentration over 480-min euglycemic clamps after subcutaneous injection of 10 units in healthy subjects (●) and 10 units (○), 30 units (□), and 50 units (▵) in obese subjects with type 2 diabetes.](zdc0121086050001){#F1}

###### 

Pharmacokinetic and pharmacodynamic parameters after subcutaneous injection of lispro

                                                          Healthy subjects (10 units)   Subjects with type 2 diabetes (10 units)          Subjects with type 2 diabetes (30 units)           Subjects with type 2 diabetes (50 units)
  ------------------------------------------------------- ----------------------------- ------------------------------------------------- -------------------------------------------------- -----------------------------------------------------------------------------------
  ka (min)                                                0.0531 ± 0.0236               0.0455 ± 0.0242                                   0.0184 ± 0.0076[§](#TF2-4){ref-type="table-fn"}    0.0179 ± 0.0091[§](#TF2-4){ref-type="table-fn"}
  *T*~max~ (min)                                          48.3 ± 4.1                    55.7 ± 14.0                                       88.6 ± 21.9                                        130\. 0 ± 46.0[‖](#TF2-5){ref-type="table-fn"}[¶](#TF2-6){ref-type="table-fn"}
  *C*~max~ (pmol/l)                                       523 ± 42                      310 ± 28                                          808 ± 218[‖](#TF2-5){ref-type="table-fn"}          1,313 ± 346[‖](#TF2-5){ref-type="table-fn"}[\#](#TF2-7){ref-type="table-fn"}
  *C*~max~/*D* (liters)                                   0.0091 ± 0.0007               0.0054 ± 0.0005[†](#TF2-2){ref-type="table-fn"}   0.0047 ± 0.0012                                    0.0046 ± 0.0012
  AUC~0-∞~ (pmol/min/l)                                   68,462 ± 17,346               60,683 ± 15,191                                   192,155 ± 46,873[‖](#TF2-5){ref-type="table-fn"}   372,571 ± 59,578[‖](#TF2-5){ref-type="table-fn"}[\#](#TF2-7){ref-type="table-fn"}
  AUC~0-∞~/*D* (min/l)                                    1.190 ± 0.302                 1.056 ± 0.264                                     1.140 ± 0.188                                      1.296 ± 0.208
  Vz (liters)                                             67 ± 16                       118 ± 34                                          104 ± 53                                           107 ± 46
  Cl (l/min)                                              0.88 ± 0.21                   0.99 ± 0.22                                       0.90 ± 0.14                                        0.79 ± 0.13
  *t*½ (min)                                              67 ± 15                       100 ± 34                                          97 ± 38                                            136 ± 72
  Mean resistance time (min)                              119 ± 21                      180 ± 65                                          196 ± 30                                           236 ± 49
  tGIR~max~ (min)                                         69 ± 12                       130 ± 23[‡](#TF2-3){ref-type="table-fn"}          175 ± 21                                           245 ± 64[‖](#TF2-5){ref-type="table-fn"}[\#](#TF2-7){ref-type="table-fn"}
  GIR~max~[\*](#TF2-1){ref-type="table-fn"} (mg/kg/min)   9.0 (7.1--11.4)               0.6 (0.4--0.9)[‡](#TF2-3){ref-type="table-fn"}    2.0 (1.4--2.7)[‖](#TF2-5){ref-type="table-fn"}     2.5 (1.7--3.7)[‖](#TF2-5){ref-type="table-fn"}
  GI~tot~[\*](#TF2-1){ref-type="table-fn"} (mg/kg)        2,299 (1,881--2,811)          92 (49--174)[‡](#TF2-3){ref-type="table-fn"}      364 (249--533)[‖](#TF2-5){ref-type="table-fn"}     678 (462--994)[‖](#TF2-5){ref-type="table-fn"}

Data are means ± SD unless otherwise indicated. There were 10 units administered in healthy subjects and 10, 30, and 50 units in obese subjects with type 2 diabetes.

\*Geometric means with 95% CI;

†*P* \< 0.001 compared with healthy controls using unpaired *t* test;

‡*P* \< 0.0001 compared with healthy controls using unpaired *t* test;

§*P* \< 0.04 compared with 10 units in subjects with type 2 diabetes using repeated-measures ANOVA;

‖*P* ≤0.002 compared with 10 units in subjects with type 2 diabetes using repeated-measures ANOVA;

¶*P* \< 0.05 compared with 30 units in subjects with type 2 diabetes using repeated-measures ANOVA;

\#*P* ≤ 0.002 compared with 30 units in subjects with type 2 diabetes using repeated-measures ANOVA.

The glucodynamic differences between healthy subjects and type 2 diabetic subjects after 10 units of lispro were considerable ([Fig. 2](#F2){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). GIR~max~ and GI~tot~ were, respectively, 7% (*P* \< 0.0001) and 4% (*P* \< 0.0001) of the value measured in healthy subjects, and tGIR~max~ was prolonged by 1 h (*P* \< 0.0001). After the 30- and 50-unit injections, GIR~max~ and GI~tot~ were different from the 10-unit values (*P* \< 0.0001 for both). After the 50-unit lispro injection, tGIR~max~ was longer than after the 10- and 30-unit injections (*P* = 0.002). GIR~max~ (*r*^2^ = 0.67, *P* \< 0.0001), GI~tot~ (*r*^2^ = 0.73, *P* \< 0.0001), and tGIR~max~ (*r*^2^ = 0.76, *P* \< 0.0001) were strongly correlated with dosage. After the 10-unit injection, the average difference between *T*~max~ and tGIR~max~ was 19 min in healthy subjects and 74 min (*P* \< 0.0007) in subjects with type 2 diabetes. The gap increased further when subjects received 30 and 50 units (86 and 115 min, respectively).

![Glucose infusion rate over 480-min euglycemic clamps after subcutaneous injection of 10 units in healthy subjects (□) and 10 units (■), 30 units (▧), and 50 units (▨) in obese subjects with type 2 diabetes.](zdc0121086050002){#F2}

When GIR was plotted as a function of lispro plasma concentrations, the sequential response-concentration relationship depicted a counterclockwise hysteresis for both healthy subjects and subjects with type 2 diabetes ([Fig. 3](#F3){ref-type="fig"}). In healthy subjects receiving 10 units of insulin, an initial GIR response of 2.22 mg/kg/min was seen with insulin concentrations nearing 40 pmol/l. Thereafter, large increases of insulin concentrations were required to increase GIR, although once the response was triggered, it was maintained while plasma concentrations decreased to 20% of the *C*~max~. In obese subjects with type 2 diabetes, after a 10-unit injection, much greater concentrations of insulin were required to produce even a minimal effect (e.g., 273 pmol/l of insulin elicited a GIR of 0.1 mg/kg/min). The response later increased abruptly to attain GIR~max~ when plasma concentrations of insulin were already dropping; once GIR~max~ was attained, the response decreased linearly with insulin plasma concentrations. The same pattern was observed for 30- and 50-unit injections.

![Plot of mean glucose infusion rate as a function of insulin plasma concentrations in healthy subjects receiving subcutaneously 10 units of lispro (●) and in obese subjects with type 2 diabetes receiving 10 units (○), 30 units (□), and 50 units (▵) of lispro. Data points are connected in chronological order; as depicted by the arrows, the resulting relationship denotes a counterclockwise hysteresis.](zdc0121086050003){#F3}

CONCLUSIONS
===========

This study characterizes the pharmacokinetic and pharmacodynamic proprieties of the short-acting insulin analog lispro in obese subjects with type 2 diabetes. After low-dose injection (10 units), lispro absorption in subjects with type 2 diabetes was as comparable as in control subjects, although the hypoglycemic effect was blunted. However, both absorption and activity were severely delayed and blunted at higher dosages (30 and 50 units) in subjects with type 2 diabetes, featuring a dose-response effect. Kinetic and dynamic parameters estimated in control subjects confirmed those published elsewhere ([@B2][@B3]--[@B4]) and support the value of our findings.

It has been repeatedly proposed, from correlations with pharmacokinetic parameters, that subcutaneous fat thickness, obesity, and low ATBF reduce insulin absorption ([@B12],[@B13]). Conversely, the present study does not confirm these facts when small dosages are administered. Insulin Vz and Cl depend on fat-free mass ([@B17]). Conversely, adipose tissue is essentially water free. Therefore, higher fat-free mass and total body water in our subjects with type 2 diabetes could explain the increment tendency in Vz, which should account for the decrease in *C*~max~ and *C*~max~/*D* when comparing with control subjects.

Within our obese subjects with type 2 diabetes presenting high daily insulin needs, we indeed expected to observe a blunted pharmacodynamic profile compared with control subjects. Moreover, we showed a dose-dependent delay of *T*~max~ and GIR~max~ at high doses in obese type 2 diabetic subjects. Similar results were found in a study done with healthy subjects using lower lispro doses ([@B18]) and in another study using inhaled insulin in subjects with type 1 diabetes ([@B19]). These effects observed at lower dose were expected to be more pronounced with higher doses in insulin-resistant subjects. Interindividual variation in insulin requirements was evaluated in overweight subjects with type 2 diabetes ([@B20]). The 8-h clamp period was not long enough to determine the entire absorption and action profile of 36 units of regular human insulin. Authors attributed these results to the possible slow insulin absorption in obese subjects with type 2 diabetes and to decreasing insulin absorption with increasing doses. They also correlated the absorbed insulin amount to daily insulin requirements. Herein, at low dosage, we did not observe a slower absorption of lispro in obese subjects with type 2 diabetes, but indeed confirmed that higher doses have a reduced effect. Thus, in obese subjects with type 2 diabetes, as ours, high insulin needs may account in part for low absorption efficiency with high doses.

As shown in [Fig. 3](#F3){ref-type="fig"}, both groups exhibited a counterclockwise hysteresis, although the magnitude was severely blunted in subjects with type 2 diabetes after 10-, 30-, and 50-unit injections. Meanwhile, GIR remained low compared with control subjects. These findings illustrate the insulin resistance expected in our obese subjects with type 2 diabetes.

Fast prandial rise in plasma and fast action of insulin are both key to adequate postprandial metabolic control. The importance of determining whether short-acting insulin analogs are efficient was recently brought into question ([@B21][@B22]--[@B23]). Several studies (rev. in [@B22]) have noted no or few benefits for these analogs relatively to human insulin in patients with type 2 diabetes as opposed to type 1 diabetes. Recent large studies ([@B24],[@B25]) provided no evidence supporting the use of preprandial insulins compared with basal insulins. The prolonged time-action profile of short-acting insulin analogs shown in this study could provide an explanation to why preprandial insulins have not had the expected benefits. In daily life, the delay in pharmacodynamic responses after short-acting analog injections may hamper postprandial metabolic control, especially when large dosages are used.

The limitation of this study relates to the impossibility to distinguish between group and dose effect, since high dosages were not tested in the control group. Testing high dosages in control subjects would indeed require intensive care management.

In summary, this study shows that absorption and hypoglycemic action of short-acting insulin analogs are critically delayed at incrementally larger dosages in obese subjects with type 2 diabetes.
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